Debiopharm International SA

Debiopharm International SA

Debiopharm International SA

Overview
Date Founded

1979

Headquarters

5-7, chemin Messidor,Lausanne, Vaud 1002

Type of Company

Private

Industries

Pharmaceuticals

Company Description

Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland.

Executives & Employees

Chief Executive Officer

General Counsel

Director, Head of Search & Evaluation & Scientific Innovation

Director, Project Management Office

Director, Business Development, Licensing, Marketing & Communication

Director, Regulatory Affairs, Business Intelligence & Market Access

Director, Quality Management & Documentation

Director, Human Resources

Director-Finance & Administration

Senior Vice President, Portfolio & Project Management

Paths to Debiopharm International SA
Potential Connections via
Relationship Science
You
Debiopharm International SA
Recent Transactions
Details Hidden

Meridian Bioscience, Inc. purchases GenePOC, Inc. from Debiopharm International SA

Details Hidden

Debiopharm International SA purchases Affinium Pharmaceuticals Ltd. from SV Health Investors LLP, Genesys Capital Partners, Inc., Forward Ventures Services LLC, Ontario Capital Growth Corp.

Transaction Advisors
Legal Advisor

Advised onDebiopharm International SA purchases Affinium Pharmaceuticals Ltd. from SV Health Investors LLP, Genesys Capital Partners, Inc., Forward Ventures Services LLC, Ontario Capital Growth Corp.

Legal Advisor

Advised onGecina purchases Eurosic SAS

Legal Advisor

Advised onDebiopharm International SA purchases Affinium Pharmaceuticals Ltd. from SV Health Investors LLP, Genesys Capital Partners, Inc., Forward Ventures Services LLC, Ontario Capital Growth Corp.

Legal Advisor

Advised onDebiopharm International SA purchases Affinium Pharmaceuticals Ltd. from SV Health Investors LLP, Genesys Capital Partners, Inc., Forward Ventures Services LLC, Ontario Capital Growth Corp.

Attorney

Advised onDebiopharm International SA purchases Affinium Pharmaceuticals Ltd. from SV Health Investors LLP, Genesys Capital Partners, Inc., Forward Ventures Services LLC, Ontario Capital Growth Corp.

Clients

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its products include ILUVIEN, Nerlynx, Probuphine, Movantik, and Neuragen. The company was founded by Jonathan R. Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

Investments
Details Hidden

GenePOC, Inc. develops rapid molecular devices to detect genes at point-of-care. Its product includes an integrated portable instrument for the prevention and early detection of infectious diseases based on a centripetal technology platform. Its product also includes GenePOC disposable, a device for performing nucleic acid-based diagnostics at POC. The company’s products are also used for infectious disease, rapid food microbiology, and human pharmacogenetic testing applications. The company was founded by Michel G. Bergeron in 2007 and is headquartered in Quebec, Canada.

Details Hidden

Diagnoplex SA develops molecular diagnostics for colon cancer. It lead product, Colox is a minimally-invasive blood test developed for the systematic screening and detection of early and advanced colorectal cancer. The company was founded in April 2005 by Stavros Therianos, Curzio Roberto Maria Rüegg, Jacques R. Essinger and Jean-Pierre Rosat and is headquartered in Lausanne, Switzerland.

Details Hidden

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Suppliers
Immunogen Inc. Medical Support Services | Waltham, MA

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Debiopharm International SA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Debiopharm International SA's profile does not indicate a business or promotional relationship of any kind between RelSci and Debiopharm International SA.